Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088465 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 931
- Enrollment target
NCT00088465: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00088465 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 931 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088465, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 931 participants
- Enrollment target
Study Summary
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: * Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, * Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment, * Determine the blood levels of IM olanzapine depot in patients during long-term treatment
Primary Outcome
The list of serious adverse events (SAE) and other non-serious adverse events (AE) are in Adverse Events Section.
Interventions
- DRUG Intramuscular olanzapine depot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 931 participants |
| Start Date | 2004-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
What the finished NCT00088465 record still lists
NCT00088465 is an interventional study that assigns participants to a tested intervention. The registered 931 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% higher).
The record links to 0 conditions, and to 1 intervention - of which Intramuscular olanzapine depot is the first listed.
NCT00088465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088465 about?
NCT00088465 is a clinical study titled "Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder". This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: * Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, ...
What is the current status of trial NCT00088465?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 931 participants. The study started on 2004-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00088465?
The interventions under investigation include: Intramuscular olanzapine depot (DRUG).
Who is sponsoring clinical trial NCT00088465?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088465's enrollment target sits among peer trials
931 338th of 2000 higher than 1,663 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia